ImmunityBio Reports Q3 Revenue of $48.7 Million, Up 53%
ImmunityBio reported net product revenue of $48.7 million for the third quarter of 2026, up 53% year over year. U.S. revenue for the first nine months rose 92% to $143.6 million. The company also reported an expanded FDA approval and an additional global approval.
Story updates
12:30:48 PM UTC
SquawkNews
Q3 net product revenue was $48.7M, up 53% year over year; nine-month revenue was $143.6M, up 92% year over year. The FDA expanded ANKTIVA’s label for BCG-unresponsive NMIBC, including papillary-only tumors.Material DetailsContext by AI AnalystThis is a commercial expansion phase, with ANKTIVA sales…
ImmunityBio, Inc. (NASDAQ:IBRX), a commercial-stage immunotherapy company, today announced continued global expansion, expanded FDA approval, and financial results for the third quarter ended September 30, 2026.ImmunityBio continued to advance a broad clinical pipeline spanning bladder cancer, non…